Weight-Loss drug tirzepatide tested in kidney transplant patients

NCT ID NCT07423247

Recruiting now Disease control Sponsor: Shahid Beheshti University of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests the safety and effectiveness of tirzepatide (Spartina) for weight loss in 30 obese adults who have had a kidney transplant at least a year ago. Participants receive weekly injections for 24 weeks, with dose adjustments based on tolerance. Researchers will track weight changes, gastrointestinal side effects, and kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide (Spartina)
What this could lead to: If it works, this could offer a safe way for kidney transplant patients to lose weight and reduce risks like heart disease and graft injury.
What could go wrong: This is a small, early pilot study with only 30 participants and no comparison group. Gastrointestinal side effects and risks to the transplanted kidney are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TIRZEPATIDE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Nooshin Dalili
RECRUITING

Tehran, Iran

Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.